FindTrial
Sign In

Development of a predictive nomogram for primary non-response to infliximab in patients with Crhon's disease

Development of a predictive nomogram for primary non-response to infliximab in patients with Crhon's disease: a multicenter study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026091
Enrollment
Unknown
Registered
2019-09-20
Start date
2019-09-19
Completion date
Unknown
Last updated
2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

Case series:infliximab

Sponsors

The First Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
9 Years to 58 Years

Inclusion criteria

Inclusion criteria: 1. A diagnosis of Crohn's disease based on clinical, radiographic, endoscopic, and histological evidence in the center; 2. Endoscopic active with Crohns disease index of severity (CDEIS) more than 3 before treatment of infliximab; 3. Complement of induction of infliximab of 5mg/kg at week 0, 2, 6 in the medical center.

Exclusion criteria

Exclusion criteria: 1. Previous ileac, colonic or ileocolonic resection; 2. Lack of ileocolonoscopy before induction of IFX or at week 14 since the first induction of IFX; 3. Incomplete data.

Design outcomes

Primary

MeasureTime frame
Primary non-response to infliximab;—

Countries

China

Contacts

Public ContactShenghong Zhang

The First Affiliated Hospital of Sun Yat-sen University

shenghongzhang@163.com+86 13570527027

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026